SCHEMBL5455786

SCHEMBL5455786

NC(=O)c1c(NC(=O)C2CC2)sc2c1CCC(F)(F)C2

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 3/20 0.67
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
REV1 Q9UBZ9 2/20 0.50
ALDH1A1 P00352 5/20 0.48
KDM4E B2RXH2 5/20 0.48
MAPT P10636 3/20 0.48
HSD17B10 Q99714 3/20 0.48
HPGD P15428 2/20 0.48
TSHR P16473 1/20 0.48
MAPK10 P53779 1/20 0.48
MDM2 Q00987 1/20 0.48
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CNR1 P21554 1/20 0.44
CNR2 P34972 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
DUSP3 P51452 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5447655 0.84 FLT3 (0.65) FLT3MEN1KMT2AREV1ALDH1A1
SCHEMBL5453513 0.82 FLT3 (0.62) FLT3MEN1KMT2AREV1ALDH1A1
SCHEMBL5467649 0.80 FLT3 (0.94) FLT3MEN1KMT2AALDH1A1KDM4E
SCHEMBL3922474 0.80 FLT3 (1.00) FLT3MEN1KMT2AALDH1A1KDM4E
SCHEMBL8288845 0.79 FLT3 (0.97) FLT3MEN1KMT2AALDH1A1KDM4E
SCHEMBL5455726 0.79 FLT3 (0.97) FLT3MEN1KMT2AALDH1A1KDM4E
SCHEMBL5449204 0.79 FLT3 (0.68) FLT3MEN1KMT2AREV1ALDH1A1
SCHEMBL5451302 0.77 FLT3 (0.70) FLT3MEN1KMT2AREV1ALDH1A1
SCHEMBL5444948 0.77 FLT3 (0.70) FLT3MEN1KMT2AREV1ALDH1A1
SCHEMBL5455042 0.77 FLT3 (0.70) FLT3MEN1KMT2AREV1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885MEN1 2891/4885KMT2A 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.